Tech Company Financing Transactions
Tikva Allocell Funding Round
On 7/22/2026, Tikva Allocell raised $8 million in Series A investment from Kantharos Capital and private investors.
Transaction Overview
Company Name
Announced On
7/22/2026
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Series A
Investors
Kantharos Capital (Lead Investor)
Proceeds Purpose
The company intends to use the funds to further enhance its IND-enabling activities and a planned year-end 2026 Investigational New Drug (IND) submission for TAVST01, its lead candidate for B7-H3-positive solid tumors.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
61 Biopolis Dr, Proteos
Singapore, 138673
Singapore
Singapore, 138673
Singapore
Phone
Undisclosed
Website
Email Address
Overview
Tikva Allocell is focused on creating therapy using our proprietary IP protected platform to drive the next breakthrough in cancer therapy. At Tikva Allocell we inspire hope today, for a better tomorrow. Tikva Allocell is established by a seasoned cell therapy development team with practical knowledge and experience, to develop effective, available and affordable "off-the-shelf" T cell therapies by leveraging excellent safety profile of Allogeneic Epstein-Barr Virus (EBV)-Specific T cells (ALLO EBVST) and proprietary IP protected technologies that enhance the T cell performance to treat cancer.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 7/22/2026: StrongestLayer venture capital transaction
Next: 7/22/2026: Candid Health venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








